Is Rhythm Pharmaceuticals Inc (RYTM) overvalued? · rev $130.1M
Rhythm Pharmaceuticals Inc (RYTM) is a biotechnology company listed on NASDAQ.
This page asks whether Rhythm Pharmaceuticals Inc (RYTM) looks expensive on cached numbers — not a short thesis.
Latest reported RYTM revenue for 2024-12-31 was $130.1M. Net income was -$260.6M. Revenue was up 68.1% from 2023-12-31 to 2024-12-31. RYTM currently screens at market cap $6.49B.
RYTM currently screens at market cap $6.49B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next RYTM 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the RYTM stock page for the full model, not this heading.
Not investment advice.